Takeda Uloric Cleared For Gout Indication
This article was originally published in The Pink Sheet Daily
Labeling for the xanthine oxidase inhibitor includes a Warning on cardiovascular safety, a concern of FDA’s.
You may also be interested in...
Advisory committee will discuss whether CARES postmarketing trial showing 34% increased risk of cardiovascular death for febuxostat warrants market withdrawal, use restrictions, or new labeling for the gout drug.
PDUFA date shifts to July 30; FDA to reschedule advisory committee.
Undeterred by a crammed proton pump inhibitor market already filled with established brand drugs, low-cost generics and over-the-counter alternatives, Takeda is moving ahead with the launch of a new PPI, Kapidex (dexlansoprazole)